Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Heidelberg Pharma

Status and phase

Completed

Phase 3

Conditions

Kidney Cancer

Renal Cell Carcinoma

Treatments

Drug: 124-Iodine-cG250 (124I-cG250)

Procedure: CT

Study type

Interventional

Funder types

Industry

Identifiers

NCT00606632

WX/20-001

Details and patient eligibility

About

This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.

Full description

A preoperative 124I-cG250 PET scan may distinguish between clear cell and non-clear cell renal carcinoma in patients with renal masses. Studies of imaging characteristics of 124I by a variety of PET cameras, quantification of tumor uptake of 124I-labeled antibody and correlation with biopsy measurement of tumor and normal tissue have met with encouraging results. As clear cell renal cancers are associated with an aggressive phenotype their a priori determination may help guide appropriate surgical/therapeutic management.

Enrollment

226 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is over 18 years of age.
Presence of a renal mass.
Scheduled for surgical resection of renal mass (partial or total nephrectomy, open or laparoscopic technique).
Expected survival of at least 3 months.
Eastern Cooperative Oncology Group (ECOG) performance status < 2.
The following laboratory results should be within the following limits within the last 2 weeks prior to study day 1:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Serum bilirubin ≤ 2.0 mg/dL
- Aspartate aminotransaminase (AST) ≤ 2.5 x ULN
- Alanine aminotransferase (ALT) ≤ 2.5 x ULN
- Serum creatinine ≤ 2.0 mg/dL (calculated creatinine clearance >45 ml/min)
Negative serum pregnancy test; to be performed on female patients of childbearing potential within 24 hours prior to receiving investigational product. All females of childbearing potential must indicate intent to avoid pregnancy and must use an accepted, effective method of contraception for the duration of the study.
Recovered from toxicity of any prior therapy.
Able and willing to give valid written informed consent.

Exclusion criteria

Metastasis of primary tumor other than Renal Cell Carcinoma (RCC).
Prior history of malignancy within the last 5 years.
Prior exposure to murine proteins or chimeric antibodies.
Intercurrent medical condition that may limit the amount of antibody to be administered.
Intercurrent medical condition that renders the patient ineligible for surgery.
New York Heart Association Class III/IV cardiac disease.
History of autoimmune hepatitis.
Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to 124I-cG250 infusion on day 1.
Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
Lack of availability for immunological and clinical follow-up assessments.
Participation in any other clinical trial involving another investigational product within 4 weeks prior to enrolment.
Women who are pregnant or breastfeeding.
Allergy to iodine, hyperthyroidism, or Grave's Disease.
Known allergic reaction to human serum albumin.
Contraindication for contrast-enhanced CT or PET/CT.
Contraindication to potassium iodide intake (see package insert).